Kagoshima University

Daicel Corporation

Kyowa Kirin Co., Ltd.

Otsuka Chemical Co., Ltd.

Ajinomoto Co., Ltd.

Jsr Corporation

Kyowa Hakko Kirin Co., Limited

Chiba University

Nihon Medi-physics Company, Limited

Yuji Ito

Nobuaki Takahashi

Ryosuke Nakano

Sayaka Maeda

Seiichi Uchimura

Yoshinari Shoyama

Akio Hayashi

Hiroyuki Suzuki

Yasushi Arano

Kazutaka Shimbo

Tetsuo Fukuta

Hiromichi Okura

Norihito Nakata

Yu Ogawa

Tomoya Uehara

Takenao Yamada

Tomohiro Fujii

Tadashi Hatano

Natsuki Shikida

Kei Yamada

Shota Komoto

Yusaku Mizuguchi

Reiko Yuji

Yutaka Matsuda

Norihiko Kiyose

Yoshihisa Hagihara

Yoko Akazawa

Nobuo Miyazaki

Tomonari Matsuda

The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.

Antibody which binds to myelin oligodendrocyte glycoprotein

This invention relates to an IgG-binding peptide, an IgG-binding peptide modified with a cross-linking agent, a conjugate of the IgG-binding peptide modified with a cross-linking agent and IgG, and a method for producing the conjugate, etc.

Specific modification of antibody with IgG-binding peptide

The purpose of the present invention is to provide a solid-phase carrier on which an IgG-binding peptide is immobilized, the peptide being usable for IgG purification, having resistance to repeated washing with an alkaline solution after IgG purification, and having a high binding affinity for IgG. Specifically, the present invention relates to a solid-phase carrier on which an IgG-binding peptide is immobilized, wherein the two cysteine residues on the outside of the peptide are linked as shown in the following formula: (in the formula, the upper cysteine residue is on the N-terminal side of the peptide, and the lower cysteine residue is on the C-terminal side of the peptide).

Solid-phase carrier including IgG-binding peptide, and IgG separation method

Provision of an affinity carrier using a mutant VHH antibody. An affinity carrier comprising: a solid phase carrier; and an immunoglobulin-binding protein bound to the solid phase carrier; wherein the immunoglobulin-binding protein comprises a mutant VHH antibody or a fragment of the mutant VHH antibody that recognizes an epitope in at least one region selected from the group consisting of amino acids 127 to 184 of SEQ ID NO: 22 and amino acids 13 to 210 of SEQ ID NO: 23.

Affinity carrier using mutant VHH antibody

The present invention relates to an IgG-binding peptide comprising a ligand capable of binding to a radioactive metal nuclide, an IgG-binding peptide labeled with a radioactive metal nuclide, a conjugate of the IgG-binding peptide and IgG, and a radionuclide imaging agent or a diagnostic agent for cancer comprising the IgG-binding peptide or the conjugate, etc.

Site-specific radioisotope-labeled antibody using IgG-binding peptide

The present invention provides a technique enabling modification of a soluble protein and in particular regioselective modification of a soluble protein. More specifically, the present invention provides a compound having an affinity substance to a soluble protein, a cleavable portion, and a reactive group represented by the following Formula (I):A-L-B-R  (I)

Compound having affinity substance to soluble protein, cleavable portion and reactive group, or salt thereof

The invention relates to an antibody which binds to chondroitin sulfate proteoglycan 5 (CSPG5) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.

Antibody binding to chondroitin sulfate proteoglycan 5

The invention relates to an antibody which binds to cell adhesion molecule 3 (CADM3) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.

Antibody binding to cell adhesion molecule 3

Described is a labeling technique which can facilitate the metabolism in the liver after administration to patients without the reduction in the antibody function, thereby reducing accumulation of radionuclides in an organ such as the liver, and a modified antibody containing an IgG antibody and an IgG-binding peptide bound to the IgG antibody. The IgG-binding peptide has an amino acid sequence consisting of 13 to 17 amino acid residues, such as GPDCAYH(Xaa1)GELVWCTFH (SEQ ID NO: 2) wherein Xaa1 represents a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid, and a compound represented by the following formula (II-1) is linked at a position of the lysine residue via a modification linker to the N terminus of the IgG-binding peptide.

Modified antibody and radioactive metal-labelled antibody

An object of the present invention is to provide a method by which a peptide having a specific binding capability that can be used for purification of a target molecule can be produced at a low cost, and specifically relates to a peptide fusion protein including one or more peptides having specific binding capability and a scaffold protein, the peptide being inserted into the amino acid sequence of the scaffold protein directly or via a peptide linker, and/or being linked to the N-terminal and/or C-terminal of the scaffold protein.

Peptide fusion protein

It is an object of the present invention to provide a method for modifying an antibody in a specific and simple manner, and others. The present invention relates to: an IgG-binding peptide, an IgG-binding peptide modified with a crosslinking agent, a complex of an IgG-binding peptide modified with the crosslinking agent and IgG, a method for producing the complex, and others.

IgG-binding peptide, and specific modification of antibody with said peptide

The present invention provides an IgG-binding peptide which can be used for the purification of IgG and has excellent stability, e.g., alkali stability. The present invention also provides a method for purifying IgG using the IgG-binding peptide. Specifically, the present invention relates to a solid-phase support including an IgG-binding peptide, an IgG separation column including the solid-phase support, a kit including the solid-phase support or the column, and a method for purifying IgG using the solid-phase support or the column.

Solid-phase support comprising IgG-binding peptide, and method for separating IgG

This invention relates to: a peptide which comprises an amino acid sequence consisting of 12 to 18 amino acid residues represented by (X)&#x2014;C&#x2014;(X)&#x2014;C&#x2014;(X) wherein each X independently represents an arbitrary amino acid residue other than cysteine, and C represents a cysteine residue, and is capable of binding to human IgA; and to a method for analyzing or purifying human IgA using the peptide.

Growing community of inventors

Kagoshima, Japan

Yuji Ito